The vision of Biologics Analysis (BA) unit is to drive the design of an innovative complex biologics by revealing a critical aspect of a molecule with global-top-level analytical capability. To achieve this vision, BA unit covers a broad range of analysis of candidate molecules from in vitro to in vivo studies: physicochemical property, binding activity to a target, pharmacokinetics property, and pharmacodynamic marker change. We support projects in every stage from lead identification to clinical candidate selection, including screening thousands antibodies, assessing manufacturability, and setting pre-formulation design. To fulfil the mission we have an access to various analytical equipment: SPR (surface plasmon resonance), HPLC, LC-MS, ELISA, ECL (electrochemiluminescence) assay, etc. Through the characterization we reveal the critical aspects of biologics and enables CPR to design and select the best candidate and develop an innovative technology.